: RNA methylation is a critical mechanism for regulating the transcription and translation of specific sequences or for eliminating unnecessary sequences during RNA maturation. METTL3, an RNA methyltransferase that catalyzes the transfer of a methyl group to the N6-adenosine of RNA, is one of the key mediators of this process. METTL3 dysregulation may result in the emergence of a variety of diseases ranging from cancer to cardiovascular and neurological disorders beyond contributing to viral infections. Hence, the discovery of METTL3 inhibitors may assist in furthering the understanding of the biological roles of this enzyme, in addition to contributing to the development of novel therapeutics. Through this work, we will examine the existing correlations between METTL3 and diseases. We will also analyze the development, mode of action, pharmacology, and structure-activity relationships of the currently known METTL3 inhibitors. They include both nucleoside and non-nucleoside compounds, with the latter comprising both competitive and allosteric inhibitors.

METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey / Fiorentino, Francesco; Menna, Martina; Rotili, Dante; Valente, Sergio; Mai, Antonello. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 1520-4804. - 66:3(2023), pp. 1654-1677. [10.1021/acs.jmedchem.2c01601]

METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey

Fiorentino, Francesco;Menna, Martina;Rotili, Dante
;
Valente, Sergio
;
Mai, Antonello
2023

Abstract

: RNA methylation is a critical mechanism for regulating the transcription and translation of specific sequences or for eliminating unnecessary sequences during RNA maturation. METTL3, an RNA methyltransferase that catalyzes the transfer of a methyl group to the N6-adenosine of RNA, is one of the key mediators of this process. METTL3 dysregulation may result in the emergence of a variety of diseases ranging from cancer to cardiovascular and neurological disorders beyond contributing to viral infections. Hence, the discovery of METTL3 inhibitors may assist in furthering the understanding of the biological roles of this enzyme, in addition to contributing to the development of novel therapeutics. Through this work, we will examine the existing correlations between METTL3 and diseases. We will also analyze the development, mode of action, pharmacology, and structure-activity relationships of the currently known METTL3 inhibitors. They include both nucleoside and non-nucleoside compounds, with the latter comprising both competitive and allosteric inhibitors.
2023
Epitranscriptomics, epigenetics, RNA, methylation, METTL3, METTL14, inhibitors, medicinal chemistry
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey / Fiorentino, Francesco; Menna, Martina; Rotili, Dante; Valente, Sergio; Mai, Antonello. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 1520-4804. - 66:3(2023), pp. 1654-1677. [10.1021/acs.jmedchem.2c01601]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1669899
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 17
social impact